EarSmartAI has secured a $250,000 pre-seed investment from Boomerang Ventures to enhance its AI-driven diagnostic platform for pediatric ear infections. This funding comes as the company aims to meet the rising demand for efficient pediatric healthcare solutions.
Located in Indianapolis, EarSmartAI is developing a connected care platform that allows parents to evaluate potential ear infections at home. Utilizing a smart otoscope, proprietary AI algorithms, and a mobile app, the platform targets the significant market of over 15 million annual pediatric ear infections in the U.S., which incurs around $5 billion in healthcare costs.
The application enables parents to input symptoms and capture video footage of the eardrum, providing an AI-generated assessment to guide care decisions. This technology aims to minimize unnecessary medical visits, enhance access to pediatric care, and facilitate earlier interventions for symptomatic children.
With over 20 years of experience in MedTech, CEO Mark Terrill will lead the company in its mission to advance toward FDA regulatory submission and commercialization. The funding will also support the completion of clinical studies and the expansion of its diagnostic platform, which is backed by research from pediatric experts at the University of Pittsburgh.
As EarSmartAI prepares for its FDA submission and commercialization, the company is focused on building partnerships in telehealth and distribution, which will be crucial for scaling its innovative solutions in pediatric care. This approach positions EarSmartAI to potentially redefine standards for at-home diagnosis of ear infections, addressing a critical need in pediatric healthcare.